INTRODUCTION
Envision a 64-year-old, athletic patient who presents to you with severe degenerative mitral regurgitation from complex bileaflet disease ( Fig. 1 ) and preserved left ventricular ejection fraction. Guidelines support intervention at this time, albeit with certain caveats [1] . Given the potential complexity of the bileaflet repair and that the patient is approaching the latter edge of the guideline-supported age window for either mechanical or biological mitral valve replacement [1] , an approach of intended mitral valve repair with implantation of a biological valve prosthesis in the event of unsuccessful repair might seem reasonable. However, in light of new findings that mortality may be higher after mitral valve replacement with a biologic prosthesis in patients <70 years of age than with a mechanical prosthesis [2] , the absolute need to successfully repair this patient's mitral valve is even more paramount.
EVOLVING INDICATIONS FOR MECHANICAL MITRAL VALVE REPLACEMENT
Mitral regurgitation is the most common clinically significant, left-sided valvular disease in the US population with an age-related prevalence ranging from 0.1% among patients 45-54 years of age to 9.3% among patients older than 75 years of age [3] . Mitral valve repair is preferred over replacement when surgical intervention is pursued [1] . However, the risk-benefit trade-off of biological versus mechanical mitral prostheses can influence the approach to mitral valve repair by virtue of the possibility that failure to durably repair the valve warrants valve replacement.
Deciding between biological and mechanical mitral valve prostheses requires individualization of care with shared decisionmaking regarding the risks and benefits of each prosthesis type. On the one hand, biological valve prostheses are at risk for structural valve deterioration with the consequent need for reoperation. On the other hand, mechanical valve prostheses are at risk for thromboembolism necessitating anticoagulation with the associated risk of bleeding and concomitant changes in lifestyle.
With improvements in the durability of biological valve prostheses, the risk of structural valve deterioration has declined; consequently, the proportion of mitral valves replaced with a biological valve prosthesis has increased [2, 4] . Furthermore, the age at which biological mitral valve prostheses may be considered appropriate has decreased over the several iterations of professional guidelines put forth by the American Heart Association (AHA) and the American College of Cardiology (ACC) [1, 5] . The most recent versions have suggested that biological mitral valve prostheses may be reasonable in patients as young as 50 years of age (Table 1) [1, 6] . This more liberal guideline for the implantation of biological valve prostheses was founded on a study by Chikwe et al. [4] examining 664 matched pairs from New York State to demonstrate that biological and mechanical mitral valves might be equivalent for patients 50-69 years of age. Given the current version of the AHA/ACC guidelines, should a durable repair not be achievable in the patient presented, a mitral valve replacement could be performed with a biological valve prosthesis with limited impact on lifestyle, i.e. the patient would not need to be anticoagulated. Additionally, there would, purportedly, be no difference in survival when compared with a mechanical mitral valve prosthesis. In this way, the risk of failed repair may appear to be low, but this supposition hinges on the survival equivalence of these valves.
Recently, our group published a population-level analysis of biological and mechanical mitral valve replacement that included 15 503 patients. Among patients who were 50-69 years of age, there was an increased risk of mortality associated with the implantation of a biological valve prosthesis [hazard ratio (HR) 1.16, 95% confidence interval (CI) 1.04-1.30; P = 0.01] as compared to mechanical valve prosthesis. There was no increase in the risk of mortality with the implantation of biological valve prosthesis among patients who were 70-79 years of age (HR 1.00, 95% CI 0.93-1.08; P = 0.97). An exploratory analysis of age as a continuous variable suggested that the transition from increased hazard of mortality to equivalence between valve types occurred at approximately 68 years of age (Fig. 2 ). As expected, there was a reduced risk of bleeding associated with biological valve prostheses compared with mechanical valve prostheses; however, there was an increased risk of reoperation [2] .
The finding that mitral valve replacement with a biological valve prosthesis was associated with increased mortality compared with a mechanical valve replacement in patients who were 50-69 years of age challenges the increasingly liberal use of biological prostheses among younger patients. Furthermore, the change in the risk-benefit trade-off for biological and mechanical valve prostheses fundamentally alters the discussion of the risks of mitral valve repair. Using a biological valve prosthesis as a fallback for a failed repair may in fact increase long-term mortality. Whether this is acceptable to the patient must be at the heart of any discussion regarding not only mitral valve replacement but also mitral valve repair.
INCREASING UTILIZATION OF MITRAL VALVE REPAIR
The ongoing controversy regarding the appropriate mitral valve prosthesis for replacement exists in the setting of both an increase in the use of mitral valve repair as an alternative to replacement and a decrease in the threshold to operate on patients with mitral valve disease. In earlier versions of professional guidelines, mitral valve repair was not recommended among asymptomatic patients with normal left ventricular function [5, 7] . Later iterations, though, have acknowledged the role of early surgery if durable repair is likely [1, 8] . Concurrent with the evolving views on indications for surgery, there appeared to be a rise in the number of mitral operations overall and a shift towards favouring mitral repair [2] . Between 2000 and 2007, the proportion of valves repaired at the time of isolated mitral valve surgery for regurgitation increased from 51% to 69% in the Society of Thoracic Surgeons Adult Cardiac Surgery Database [STS ACSD] [9] . Subsequent data coming from the STS ACSD has demonstrated a slight decline in the overall rate of repair from 67.1% in 2011 to 63.2% in 2016, though the rate of repair for degenerative disease was substantially higher at 82.5% for the time period. Notably, 43.1% of patients in the STS ACSD undergoing isolated mitral valve surgery between 2011 and 2016 were asymptomatic; the majority of asymptomatic patients had triggers for surgery [10] . Furthermore, the majority (66.8%) of patients in New York State undergoing mitral valve surgery between 2002 and 2013 underwent mitral valve repair with the remaining being replacements [11] . Although both the AHA/ACC and the European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) guidelines recommend mitral valve repair over mitral valve replacement when a durable repair may be achieved [1, 12] , durable repair is not always possible. The possibility of replacement has an important effect on both the decision to operate and the surgeons performing the operation.
The AHA/ACC and ESC/EACTS guidelines differ with respect to both the strength of the recommendation and the threshold to intervene for asymptomatic patients with chronic severe primary mitral regurgitation. Although the ESC/EACTS guideline puts forth a Level IIa recommendation for mitral valve repair when durable repair is 'likely' in patients with preserved ejection fraction (>60%) and the left ventricular end-systolic diameter of 40-44 mm [12] , the most recent AHA/ACC guideline offers a Level I recommendation for similar patients without a qualification regarding the likelihood of repair (Table 2 ) [1] . Moreover, among patients with normal ejection fraction and no evidence of ventricular dilatation (left ventricular end-systolic diameter <40 mm), the recommendation from the ESC/EACTS guideline is for close follow-up at a heart valve centre. In contrast, mitral valve repair 'is reasonable' (Level IIa recommendation), according to the AHA/ACC guidelines, for similar patients, if the likelihood of success is >95% and the mortality rate is <1% (Table 2 ) [1] . With the evolution in the indication for mechanical mitral valve replacement, the AHA/ ACC guideline may need to raise the bar for success or become more conservative with respect to the threshold for operation.
Whether the ESC/EACTS is too conservative remains to be determined. Surgeon experience may influence the success of mitral valve repair [11, 13] , and mitral valve reference groups have reported near-100% repair rates for degenerative disease [14, 15, 16] . Societal guidelines emphasize the importance of a high probability of success when undertaking repair for asymptomatic disease with preserved left ventricular function [1, 12] , and this is due to the negative consequences of failed repair. Among patients 50-69 years of age, the failure to perform a durable repair of the mitral valve would either necessitate replacement with a mechanical valve or introduce the possibility of mid-term reoperation due to either a faulty repair or structural valve deterioration of a biological valve prosthesis with a concomitant increase in the risk of mortality during the follow-up.
Whether anticoagulation or an increased risk of mortality might be acceptable to a healthy 64-year-old patient who remains physically active is uncertain and likely varies from patient to patient. With even a modest chance of replacement, one may consider referring this patient to a reference centre.
RISK OF REOPERATION
The risk of mortality associated with mitral valve reoperation contributes to the increased hazard of death associated with biological valve prostheses. In the state of California, mitral valve replacement after a prior replacement was associated with a 14.0% risk of perioperative mortality [2] . This finding was consistent with a study from the Virginia Society of Thoracic Surgeons regional database reporting 11.1% perioperative mortality for reoperation following prior repair or replacement.
Transcatheter technology may be an attractive alternative to reoperative mitral surgery, and the possibility of transcatheter valve-in-valve replacement has already been included in the guidelines as part of the discussion regarding biological versus mechanical valve prostheses [1] . The multicentre transcatheter mitral valve replacement registry has reported outcomes in 248 patients with 6.5% periprocedural mortality for both valve-invalve and valve-in-ring procedures. However, device success was 89.2% for valve-in-valve procedures and a modest 76.4% for valve-in-ring procedures [17] . With the evolution of transcatheter technologies and improvements in technique, these procedures will no doubt become safer and more successful. However, these methods in their current state may not adequately serve as salvage procedures for either imperfect mitral valve repair or structural valve deterioration of biological mitral valve prostheses and probably should not dominate operative decision-making at this time.
CONCLUSION
The role of mitral valve repair will change with the evolution of recommendations for mechanical mitral valve replacement. The development of biological valves that are more resistant to structural valve deterioration and improvements in transcatheter technology may narrow the observed survival gap between biological and mechanical mitral valve prostheses. However, until this speculation becomes a reality, mechanical mitral valve prostheses remain the gold standard for valve replacement in younger individuals. The possibility of lifelong anticoagulation with the implantation of mechanical mitral valve prosthesis must be a significant part of the shared decision-making process when offering mitral valve repair to patients younger than 70 years of age. Given the risk of reoperation with biological valve prostheses, the failure to perform a durable mitral valve repair may accidentally impart a mortality burden on the patient. Strong consideration should be given to referring patients with complex mitral valve disease to centres where the likelihood of repair is exceptionally high.
